Eam Investors, LLC Prothena Corp Public LTD CO Transaction History

Eam Investors, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$48.26 - $78.59 $651,510 - $1.06 Million	13,500 Added 37.34%	49,656 $3.39 Million
Q1 2023 Jul 12, 2023	BUY	$46.97 - $58.27 $1.7 Million - $2.11 Million	36,156 New	36,156 $1.75 Million
Q4 2022 Feb 14, 2023	SELL	$52.05 - $65.0 $15,146 - $18,915	-291 Reduced 0.54%	53,346 $3.21 Million
Q3 2022 Nov 14, 2022	BUY	$25.16 - $60.63 $1.35 Million - $3.25 Million	53,637 New	53,637 $3.25 Million
Q4 2021 Feb 11, 2022	SELL	$42.11 - $73.26 $2.72 Million - $4.74 Million	-64,650 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$48.2 - $78.89 $1.92 Million - $3.15 Million	-39,900 Reduced 38.16%	64,650 $4.61 Million
Q2 2021 Aug 13, 2021	BUY	$21.63 - $57.65 $927,775 - $2.47 Million	42,893 Added 69.57%	104,550 $5.38 Million
Q1 2021 May 11, 2021	BUY	$11.0 - $28.24 $678,227 - $1.74 Million	61,657 New	61,657 $1.55 Million

190

42.9M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $661M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.